MAP2K7 and breast carcinoma: Indeed, TMEM16A has been reported to activate EGFR and CAMKII signaling in breast cancer cells [42], p38 and ERK1/2 signaling in hepatoma cells [52], Ras-Raf-MEK-ERK1/2 signaling in UM-SCC1 HNSCC cells and T24 bladder cells [44], and NFκB signaling in glioma cells [56] (Table 1), supporting that TMEM16A activates different signaling pathways in a cell type-dependent way.